BiotechTube

Mebendazole

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Newly Diagnosed High-Grade Glioma

Conditions

Newly Diagnosed High-Grade Glioma

Trial Timeline

Apr 4, 2013 → Apr 16, 2021

NCT ID
NCT01729260

About Mebendazole

Mebendazole is a phase 1 stage product being developed by Brain Biotech for Newly Diagnosed High-Grade Glioma. The current trial status is completed. This product is registered under clinical trial identifier NCT01729260. Target conditions include Newly Diagnosed High-Grade Glioma.

What happened to similar drugs?

0 of 5 similar drugs in Newly Diagnosed High-Grade Glioma were approved

Approved (0) Terminated (1) Active (4)
🔄Olaparib 300mg tabletsAstraZenecaPhase 3
🔄Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimenAmgenPhase 3
🔄Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + DexamethasonePfizerPhase 3
❌Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3
🔄Bortezomib + Isatuximab + Iberdomide + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01729260Phase 1Completed

Competing Products

18 competing products in Newly Diagnosed High-Grade Glioma

See all competitors
ProductCompanyStageHype Score
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
Gliadel Wafer + TemozolomideEisaiPhase 2
31
Olaparib 300mg tabletsAstraZenecaPhase 3
44
PembrolizumabMerckPhase 2
39
Drug (including placebo)MerckPhase 1
21
CilengitideMerckPhase 2
31
[177Lu]Lu-NeoB + [68Ga]Ga-NeoBNovartisPhase 1
33
BKM120 + Trastuzumab + Paclitaxel + BKM120 PlaceboNovartisPhase 2
35
Tecentriq 1200 MG in 20 ML Injection + H3K27M peptide vaccineRochePhase 1
33
ZenapaxRochePhase 2
35
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimenAmgenPhase 3
47
Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + DexamethasonePfizerPhase 3
47
Elranatamab + Daratumumab + LenalidomidePfizerPhase 2
42
Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3
32
Bortezomib + Isatuximab + Iberdomide + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 3
47
Isatuximab-Irfc 20 MG/ML [Sarclisa] + Lenalidomide + Dexamethasone OralSanofiPhase 2
39
Balstilimab + Botensilimab + Liposomal DoxorubicinAgenusPhase 2
32
HLA-A2 restricted glioma antigen peptides vaccine + Poly-ICLCBrain BiotechPhase 1
19